Introduction
Type 2 diabetes mellitus (T2DM) develops as a consequence of an interplay between peripheral insulin resistance and β -cell dysfunction. Insulin resistance is an early abnormality which is usually attributed to obesity. During the prediabetic period, the presence of insulin resistance does not initiate a noticeable glucose increase in plasma because of β -cell adaptation that permits the maintenance of normal glucose metabolism. However, pancreas β -cell function will gradually decline over time and this adaptation will eventually fail, owing to both genetic and environmental factors. Overt T2DM will appear. Growing evidence supports decreased functional β -cell as the hallmark of T2DM (Marchetti et al., 2006) .
T2DM is a syndrome that has been defined as 'a group of metabolic disorders', which
indicates that T2DM has a multifactorial pathogenesis, including genetic, epigenetic, and environmental factors. Several lines of evidence suggest that T2DM is highly associated with a generalized activation of the innate immune system, in which a chronic and systematic low-grade inflammation is involved (Wellen and Hotamisligil, 2005) . Chronic inflammation can cause insulin resistance in adipose tissue, skeletal muscle, and liver by inhibiting insulin signaling via autocrine/paracrine/endocrine pathways (Olefsky and Glass, 2010) . Chronic inflammation in islet cells has been characterized by the presence of cytokines, immune cells, and amyloid deposits, which contribute to the decrease in β -cell mass and the impaired function (Donath et al., 2009; Ehses et al., 2009a) . Further evidence for roles of chronic inflammation in T2DM
comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β antagonism and salsalate treatment (Larsen et al., 2007; Goldfine et al., 2008) .
The application of model-based approaches to gain insight into disease progression is widely accepted in the field of diabetes and anti-diabetic drug development (Gobburu and Lesko, 2009 ).
However, human T2DM often takes years to develop and it is costly to assess the effect of interventions on the whole process of clinical diabetes. Animal models allow interventions to be assessed in much shorter time spans. Goto-Kakizaki (GK) rats provide a polygenic model for spontaneous T2DM by inbreeding Wister rats with glucose intolerance for more than 30
generations. Unlike clinical T2DM in which obesity commonly occurs, GK rats show similarity with humans in terms of polygenetic and multifactorial pathogenesis (Portha et al., 2009 ).
Chronic inflammation has been found to be closely associated with diabetic status in GK rats (Almon et al., 2009; Xue et al., 2011) . Thus GK rats should be a suitable rodent model for assessing diabetes progression especially when evaluating the roles of chronic inflammation.
Salsalate, a nonacetylated prodrug of salicylate, has shown potential for decreasing blood glucose concentrations by decreasing inflammation in several clinical studies (Koska et al., 2009; Goldfine et al., 2010) . However, the effects of salsalate on diabetes disease progression have not been investigated. Our study assesses the potential effect of salsalate on diabetes progression in GK rats. In addition, chronic inflammation is closely associated with an enlarged body mass and reducing inflammation might influence weight gain. Thus, another aim of our study is to explore the influence of salsalate on weight gain and energy expenditure.
Blood glucose was measured using a BD Logic blood glucose meter (BD Medical, Franklin Lakes, NJ). Blood salicylate was measured using a previously reported HPLC method (Harrison et al., 1980) with minor modification by lowering mobile flow rate from 2.0 to 1.5 ml/min for system protection. The quantification limits was 1.6 μ g/ml for both salsalate and salicylic acid with less than 10% intra-batch variability.
Models Salicylate Pharmacokinetics
As a consequence of the gradual reduction of food intake with aging, the blood concentrations of salicylic acid declined and the pooled profile was characterized using:
where C b is salicylate blood concentration, C 0 is the initial concentration at the beginning of fed, C max represents the maximum decrease of blood concentration with aging, and T 50 is the time at which salicylate concentrations decreased by half of the maximum.
Disease Progression Model
The GK rats are a spontaneous diabetic model which is characterized by moderate insulin resistance (Bisbis et al., 1993) , impaired glucose-induced insulin secretion (Portha et al., 1991) , and progressive loss of β -cells function (Movassat et al., 1997) . Insulin resistance and impaired β -cell function are both early events that contribute to the onset of diabetes in GK rats. Insulin resistance is found to be moderate and did not deteriorate with aging (Berthelier et al., 1997) .
Progressive β -cell deterioration has been found as a primary defect contributing to establishment of overt diabetes in GK rats (Movassat et al., 1997) .
Based on these disease characteristics, insulin resistance and β -cell dysfunction were considered as two main disease components in modeling the diabetes progression in GK rats. Fig. 1 depicts the general schematic for disease progression model that is integrated with salicylate pharmacodynamics. Blood glucose concentrations were characterized using an indirect response model (Dayneka et al., 1993) . Since we measured fed glucose concentrations, the main regulation of glucose by insulin is enhancing glucose utilization in peripheral tissues rather than inhibition of glucose production by liver. Therefore, two assumptive disease elements were incorporated to inhibit glucose utilization and described by,
where Glu represents blood glucose concentration. Glucose is produced by zero-order rate constant k in_glu , including absorption from nutrition and gluconeogenesis by the liver, k out_glu is the first-order utilization rate constant by peripheral tissues, S in and BF m are two assumed disease components, S in is progressive worsening of insulin resistance, and BF m represents gradual deterioration of β -cell function. The two factors multiply each other to jointly reduce glucose utilization. The initial condition of Glu is GLu(0), which was estimated.
Two transduction cascades are applied to mimic gradual occurrence of two critical disease elements. Age-related development of insulin resistance is described by a function of S in with a series of transit compartments which is initiated by a disease factor constant k dis1 . All compartments in this transduction cascades are described by differential equations that maintain homeostasis when unperturbed. The worsening process of insulin resistance is described by,
where S in indicates the nth transit compartment relevant to the series of events of insulin resistance that take place before the increase in blood glucose. The value of k r indicates the turnover rate constant for each compartment in this series. The initial conditions for all transit compartments are 0, assuming no worsening of insulin resistance occurs before initiation by disease factor k dis1 . Different transit compartment numbers were tested to find a number that sufficiently captured the glucose profile accounting for both a large delay and rapid rise to a new disease steady-state. The interpretation of each compartment is not straightforward and they are not components of a series of real events that occur during the disease process.
The β -cell dysfunction process was characterized similarly to that of insulin resistance. A series of transit compartments initiated by a disease factor constant k dis2 was employed to describe the continuous change of β -cell dysfunction. The first and last transit compartments are:
where BF m represents the nth transit compartment relevant to β -cell dysfunction and k d is transduction rate constant. The transit compartment number was optimized to capture the data as best as possible. The initial conditions for all transit compartments were assumed to be 1 because this event happened later than insulin resistance and no influence was considered before the initiation of β -cell deterioration.
One important clarification about the two disease factors is that both S i and BF i represent disease worsening process and predisposed disease is not accounted for in this model. Thus, S i = 0 or BF i = 1 represent no worsening of disease compared to the starting time of the experiment (4 weeks of age), rather than no abnormality being present at that time.
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Salicylate Pharmacodynamics
To integrate salicylate effects into the diabetes progression model, different approaches were tested, including modifying the transduction rate constants, reducing disease factor constants k dis1 and k dis2 , and different combinations of both. The final model is shown in Fig. 1 . Salicylate was assumed to ameliorate diabetes progression by decreasing both disease factors, in which a transduction model was used to describe the delayed protective effect on insulin resistance by salicylate and the suppressive effect on β -cell dysfunction was expressed by directly decreasing the disease factor k dis2 . The effect on insulin sensitivity was assumed to be linearly associated with salicylate concentrations. The protective effect on β -cell function was handled as a constant (E 2 ) because salicylate blood concentrations did not change much during the period of β -cell accelerated deterioration. The following equations describe the pharmacodynamics of salicylate on the diabetes progression in these GK rats: 
Growth Model
The mechanism-based growth model was originally developed by our lab based on basic principles of physiology and biology (Landersdorfer et al., 2009 ). The complete model includes food intake, abdominal fat weights, and total body weight as well as leptin concentrations. The model applied in this study was derived from the original model with a simplification of the food intake component. Because leptin was not analyzed in this study, food intake was handled as a time-dependent variable rather than influenced by leptin concentrations. The model diagram is shown in Fig. 1 . Body weight growth was described as:
where Food is food consumption per day (kilocalories/day), BW is body weight (g), Fat is total body fat, (BW-Fat) represents an estimate for lean body mass (LBM), metabolic rate R is associated with allometrically scaled LBM derived from the equation by West et al (West et al., 2003) , and EF is the efficiency of conversion of unmetabolized energy to body weight.
Previously, food intake was first found to increase and then slightly decrease with aging, but in this study no decreasing tendency was observed. The food intake was described with the 'monomolecular equation ' (Madden, 1980) as:
where k g is the rate constant for increase in food intake and F max is maximum food intake.
Total body fat was estimated from abdominal fat mass (Newby et al., 1990) , which was captured by the Weibull function,
where AFat is abdominal fat mass, Bf and cf are constants and fixed, and IP is the inflection point of the Afat growth curve.
Parameter Variability and Observation Model
The inter-individual variability was described by an exponential parameter variability model.
The unidentified random variability was described by a combined additive and proportional error model for glucose and only additive error model was used for food intake and body weight change.
Computation
The diabetes progression combined with salicylate effect was modeled using S-ADAPT (V1.56, beta) with the Monte Carlo Parametric Expectation Maximization algorithm (MC-PEM).
The SADAPT-TRAN translator tool was used to facilitate S-ADAPT analyses. The disease progression and pharmacodynamic model were fitted simultaneously. Body weight and food intake modeling was performed using NONMEM VI via first order conditional estimation method with interaction (FOCE, NONMEM Project Group, University of California, San
Francisco, CA). Body weight and food intake were fitted jointly. All parameters of the growth model were first estimated with independent typical values and inter-subject variability for each group, and then combined if their estimates were similar among groups. Salicylate
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Results

Salicylate Pharmacokinetics
The parent drug salsalate concentrations were below the quantification limit for all blood samples collected during diet feeding, indicating salsalate was almost completely hydrolyzed into salicylic acid during absorption. Initially, we planned to describe daily salicylate profiles based on a two-compartment model with rat eating rates as an input. However, the high variability of rat eating behaviors made it challenging to describe daily profiles. Instead, we Table 1 .
Glucose Dynamics
The changes in blood glucose concentrations are shown in Fig and the second phase appeared at 14-15 weeks with a glucose upsurge of more than 100 mg/dL.
Interestingly, in the GK disease group, the second phase was much higher in three rats than the others and diabetes seemingly showed two degrees of severity. Such severity was not handled separately in our model and was ascribed to inter-individual variability. Salsalate significantly attenuated the glucose rise in both phases (p < 0.05, ANOVA) producing nearly flat glucose profiles.
Disease Progression Model
The individual glucose profiles and model predictions are shown in Fig. 4 . The biphasic profiles were reasonably captured by the disease progression model, in which the first phase was associated with insulin resistance and second surge was related to the subsequent occurrence of β -cell deterioration. The optimized transit compartment number for insulin resistance cascade is 5 and for β -cell deterioration cascade is 98. The two numbers were then fixed in the final model fitting. Final estimated parameters and between-subject variability are summarized in Table 2 .
All parameters were estimated with reasonable precision. Goodness-of-fit plots indicate the population method seems to considerably improve model fitting. The contributions to blood glucose changes from the two disease components can be estimated by the concentrations in the last transit compartments, shown as 0.091 (k dis1 /k r ) for insulin resistance and 3.76
Based on the approach we formulated for describing disease progression with the two disease elements in equation (2), the k dis1 was estimated to account for 10% and k dis2 seemed to account for 60% of the glucose rise compared to initial glucose concentrations. The model, as shown in Fig. 4 , is reasonable and adequately reflects the trend and variability of the raw data.
Salsalate Pharmacodynamics
The pharmacodynamic parameters and inter-individual variability are listed in Table 2 . The ameliorative effect of salsalate on diabetes progression was sufficiently described by the present model. Other models that were tried to incorporate salsalate effects in other ways did not generate good fittings or resulted in imprecise parameter estimates. The suppressive fractions of salsalate on two disease factors were calculated and the fraction on insulin resistance was estimated as 0.62 (C b ·E 1 /k t ) and on β -cell deterioration as 0.14 (E 2 ). As indicated in Table 2, inter-subject variability was not precisely estimated for E 1 , k d , and k t , which may be related to insufficient sample size and high inter-subject variability. Even so, as shown in Fig. 4 , the pharmacodynamic model provides a satisfactory predictive performance by visual predictive checks.
Simulation profiles of the two disease components are shown in Fig. 5 . The onset of salsalate effect on insulin resistance is about 1.5 weeks after treatment. Due to the decline of salicylate concentrations over time, the suppressive effect slightly decreased after 9 weeks of age for disease factors 1. The accelerated deterioration of β -cell function appeared at around 14-16 weeks, and salsalate showed moderate improvement on β -cell deterioration.
Growth Model
The individual observed body weights and predicted curves are shown in Fig. 6 . The parameters for the growth model are listed in Table 3 . Body weights at the start of the study were similar for all groups. The control GK rats reached slighter higher body weights compared to salsalate fed GK rats, despite similar energy intake. Assuming all GK rats require the same This article has not been copyedited and formatted. The final version may differ from this version. energy, the predicted body weights are still higher in control than salsalate groups, suggesting that energy intake alone cannot account for all the growth differences. The efficiency of converting energy (EF) which is not transformed to body weight was considerably higher in GK than in WKY rats, in line with our previous report (Landersdorfer et al., 2009 ). The metabolic rate (R) per gram of LBM 0.75 was significantly greater in salsalate fed GK rats than control GK (p < 0.05), and all GK rats showed slightly higher R than WKY rats. The R of LBM was also higher in salsalate fed WKY rats than control WKY rats, suggesting that the effect of enhancing R of LBM by salicylate was not limited to GK strains.
Observed energy intake and the predicted curves are shown in Fig. 7 . Energy intakes were slightly lower in salsalate treatment groups, for both GK and WKY rats. Maximum food intakes were estimated higher in GK than WKY rats, which is inconsistent with previous findings. Two reasons might account for this. One might be related to the different sources of WKY rats.
Another explanation might be the different tasting propensity between GK and WKY, because the present diet had distinctive compositions and bacon flavor was formulated for better taste.
Three rats were excluded from this analysis, all from WKY rats, two from salsalate fed group, one from control group. These rats were suspected to have gastrointestinal tumors by visual check at the end of experiment. The reason for this is not quite clear and it is not related to salsalate treatment.
This article has not been copyedited and formatted. The final version may differ from this version. , 1997; Gao et al., 2011) .
Shown in our results, the sharp rise of glucose appeared around 14-16 weeks (Fig. 3) , consistent with the reported time of substantial β -cell deterioration. Therefore, it is rational to assume that disease factor 2 that happens around 15 weeks represents overt β -cell failure.
In GK rats, insulin resistance was found to be moderate and would not progressively suggests the state of insulin resistance, which was observed at 8 weeks of age in GK rats from our previous study (Gao et al., 2011) . Collectively, although not being a primary defect of diabetes in GK rats, insulin resistance is an important factor contributing to glucose intolerance before overt diabetes. As shown in Fig. 5 , insulin resistance appeared at 4-5 weeks and contributed to the first phase of increased glucose, consistent with previous observations that insulin resistance developed before overt hyperglycemia.
Functional adaptation between insulin resistance and β -cell function has been widely investigated in human T2DM. Nonetheless, it has not been well established in GK rats. As known in GK rats, the glucose-induced insulin response is impaired and resistance may not inflammation in GK rats is still inconclusive but one thing that is apparent is that the inflammation is not fat driven because GK rats are a diabetic model exhibiting a non-obese phenotype. Therefore, one of our objectives in this study is to test the hypothesis that chronic inflammation regardless of source plays a causal role in T2DM. As indicated in Fig. 3 There may be different levels and roles of inflammation in tissues that control diabetes progression.
Another issue addressed in the present study was the potential effect of salsalate on weight gain and energy expenditure in GK rats. Higher energy expenditure is expected in obesity or diabetes. The growth model indicated that a higher metabolic rate (R) was present in GK rats than age-matched WKY rats, consistent with previous observation (Landersdorfer et al., 2009).
Salsalate was suggested to enhance R and resulted in lower body weight compared to the control group. Such an effect of salsalate was present in both GK and WKY, indicating the action is independent of diabetic status. Similar effects were seen clinically that salsalate stimulated whole body energy expenditure by increasing oxidative glucose disposal, which might be attributed to 
Conclusions
The proposed model satisfactorily captured the biphasic glucose rise in GK rats from 4 to 21 weeks age by assuming two disease cascades to mimic insulin resistance and β -cell dysfunction.
Salsalate substantially ameliorated diabetes progression and resulted in flat glucose profiles. Our model incorporates anti-inflammatory effects in the characterization of diabetes progression.
Expanding this model by including specific inflammatory factors will be beneficial in gaining further understanding on the causal role of inflammation on diabetes progression and in designing related pharmacological studies. . Legends for Figures   Fig. 1 
